ArticleClinical, cosmetic and investigational dermatology2019
The efficacy of glycolic acid, salicylic acid, gluconolactone, and licochalcone A combined with 0.1% adapalene vs adapalene monotherapy in mild-to-moderate acne vulgaris: a double-blinded within-person comparative study.
Article in Clinical, cosmetic and investigational dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Efficacy and safety of a new peeling formulated with a pool of PHAs for the treatment of all skin types, even sensitive.Journal of cosmetic dermatology · 2023Trial
- A Double-Blinded, Randomized, Vehicle-Controlled Study of the Efficacy of Moisturizer Containing Licochalcone A, Decanediol, L-Carnitine, and Salicylic Acid for Prevention of Acne Relapse in Asian Population.BioMed research international · 2020Trial
- Integrating Dermocosmetics Into Acne Care in Latin America.Journal of cosmetic dermatology · 2026Review
- International expert consensus recommendations for the use of dermocosmetics in acne.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Therapeutic potential of Licochalcone A in dermatological diseases: from basic to clinical research.Frontiers in pharmacology · 2025Review
- Bioactivation of Konjac Glucomannan Films by Tannic Acid and Gluconolactone Addition.ACS applied materials & interfaces · 2024Article
- Liposomes and Other Nanocarriers for the Treatment of Acne Vulgaris: Improved Therapeutic Efficacy and Skin Tolerability.Pharmaceutics · 2024Review
- Resolving acne with optimized adapalene microspongeal gel, in vivo and clinical evaluations.Scientific reports · 2024Article
- Investigation on the Biological Safety and Activity of a Gluconolactone-Based Lotion for Dermocosmetic Application.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Measurement of the effects of the IMAGE MDGMS Interdisciplinary plastic and reconstructive surgery DGPW · 2022Article
- Investigation of the precision of the VisiaGMS Interdisciplinary plastic and reconstructive surgery DGPW · 2022Article
- Validation of the VisiaGMS Interdisciplinary plastic and reconstructive surgery DGPW · 2022Article
- A Narrative Review on the Role of Acids, Steroids, and Kinase Inhibitors in the Treatment of Keratosis Pilaris.Cureus · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcne vulgaris is a common and chronic disease that impacts on physical and psychological perceptions. Cosmeceutical products are widely used as adjunct therapy to standard treatments.
objectiveTo evaluate the efficacy of cosmeceutical products comprising glycolic acid, salicylic acid, gluconolactone, and licochalcone A as adjunct therapy to adapalene in mild-to-moderate acne vulgaris. MATERIALS AND
methodsA 28-day, double-blind, within-person comparative study was conducted with a total of 25 subjects. Each participant received two products, consisting of (1) a cosmeceutical product mixed with 0.1% adapalene, and (2) 0.1% adapalene, and was asked to apply them separately on each hemi-side once nightly for 28 days. The number of acne lesions, severity of acne vulgaris, physician's and patient's global assessment of acne severity, visual analog scale of radiance, skin biophysics, safety assessment, and VISIA
resultsThe mean differences of inflammatory lesions reduction at day 7 between the two groups was 0.391 (90% CI = 0.253-0.530). The differences between two groups fell within our acceptable margin for the 90% CI. The spot score from VISIA
conclusionThe results showed no hindrance of using a cosmeceutical combined with standard treatment. Nevertheless, this cosmeceutical product showed some benefits in reducing complications from acne. CLINICAL
trial registrationThai Clinical Trials Registry (primary site), no. TCTR20171031005.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.